Dario Health continues to introduce products that enable individuals to effectively keep tabs on their own health. The company that started with a single device to enable users to monitor their blood glucose level throughout the day (a device that is extremely...
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its suite of digital therapeutics for diabetes, hypertension and pre-diabetes to a Northeast regional employer ("Employer"). The contract...
Igentify has raised $10.5 million in an A-Round funding. Moon Partners closed the round with a $6.5 million investment. The other investor in the round is Jerusalem-based, Our Crowd. The new round brings the total raised by the company to $15.5 million,...
MD Clone Empolyees
MD Clone has raised $26 million, in a new funding round. Leading the new investment is the aMoon fund of Mauris Nacht, one of Check Point’s founders. Also participating were the current investors OrbiMed and Lightspeed Venture Partners. MD Clone...
OurCrowd, today announced that it would lead a $12 million investment in the newly formed MigVax Corp., which will develop a novel COVID-19 vaccine. MigVax, an affiliate of The Migal Galilee Research Institute, is pioneering the effort to develop Israel’s human vaccine...
1-800 Contacts has entered into a contract to purchase Tel Aviv-based 6over6 vision. While the exact price was not disclosed, the speculated sum of the purchase is over $100 million. 6over6 has created software that allows a complete eye exam to administered...
Teva Israel's leading pharmaceutical company released its quarterly and 2019 results today. They showed an improvement from 2018 as losses narrowed.
Full-Year 2019 and Q4 2019 Highlights: FY 2019 Q4 2019 Revenues $16.9 billion $4.5 billion Revenues prior to revision (*) $17.5 billion $4.6 billion Cash flow...
Teva Pharmaceuticals has reached a settlement with Cuyahoga and Summit counties of Ohio to settle claims in the Opioid addiction lawsuit. Under the terms of the settlement, Teva will provide buprenorphine-naloxone (sublingual tablets), known by the brand name Suboxone®, valued at $25...
